POPULATION BASED STUDY OF THE PREVALENCE OF EGFR MUTATIONS IN NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Skov, Birgit G. [1 ]
Hogdall, Estrid [2 ]
Clementsen, Paul [3 ]
Krasnik, Mark [1 ]
Larsen, Klaus R. [4 ]
Sorensen, Jens B. [1 ]
Mellemgaard, Anders [5 ]
机构：
[1] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
[2] Herlev Univ Hosp, Herlev, Denmark
[3] Gentofte Univ Hosp, Hellerup, Denmark
[4] Bispebjeg Univ Hosp, Copenhagen, Denmark
[5] Univ Copenhagen, Herlev Univ Hosp, DK-1168 Copenhagen, Denmark
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR mutations; Cytology; population based; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.06-022
引用
收藏
页码：S1082 / S1083
页数：2
相关论文
共 50 条
  • [41] Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer
    Akca, Hakan
    Demiray, Aydin
    Yaren, Arzu
    Bir, Ferda
    Koseler, Aylin
    Iwakawa, Reika
    Bagci, Gulseren
    Yokota, Jun
    CANCER GENETICS, 2013, 206 (03) : 73 - 80
  • [42] Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients
    Scodes, Simona
    Cappuzzo, Federico
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2020, 14 (06) : 565 - 576
  • [43] New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations
    David, Gil-Sierra Manuel
    del Pilar, Briceno-Casado Maria
    Cristina, Moreno-Ramos
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (04) : 934 - 943
  • [44] COMMON AND UNCOMMON EGFR MUTATIONS AND THEIR IMPACT ON RESPONSE TO EGFR TYROSINE-KINASE INHIBITORS AND PLATINUM-BASED CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER (NSCLC): LATIN-AMERICAN CONSORTIUM FOR THE INVESTIGATION OF LUNG CANCER (CLICAP)
    Arrieta, Oscar
    Cardona, Andres
    Campos Parra, Alma D.
    Corrales-Rodriguez, Luis
    Sanchez-Reyes, Roberto
    Katherine Rodriguez, July
    Carranza, Hernan
    Vargas, Carlos
    Zuniga-Orlich, Carlos
    Juarez-Villegas, Melissa
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S482 - S482
  • [45] Immunotherapy in non-small cell lung cancer harbouring driver mutations
    Addeo, Alfredo
    Passaro, Antonio
    Malapelle, Umberto
    Banna, Giuseppe Luigi
    Subbiah, Vivek
    Friedlaender, Alex
    CANCER TREATMENT REVIEWS, 2021, 96
  • [46] Staging of non-small cell lung cancer (NSCLC): A review
    Tsim, S.
    O'Dowd, C. A.
    Milroy, R.
    Davidson, S.
    RESPIRATORY MEDICINE, 2010, 104 (12) : 1767 - 1774
  • [47] Brain metastasis in non-small cell lung cancer(NSCLC) patients with uncommon EGFR mutations:a report of seven cases and literature review
    Puchun Er
    Tian Zhang
    Jing Wang
    Qingsong Pang
    Ping Wang
    Cancer Biology & Medicine, 2017, (04) : 418 - 425
  • [48] Patients with Non-small Cell Lung Cancer Analyzed for EGFR: Adherence to Guidelines, Prevalence and Outcome
    Sandelin, Martin
    Berglund, Anders
    Sundstrom, Magnus
    Micke, Patrick
    Ekman, Simon
    Bergqvist, Michael
    Bergstrom, Stefan
    Koyi, Hirsh
    Branden, Eva
    Janson, Christer
    Botling, Johan
    ANTICANCER RESEARCH, 2015, 35 (07) : 3979 - 3985
  • [49] Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
    Agulnik, Jason S.
    Papadakis, Andreas I.
    Pepe, Carmela
    Sakr, Lama
    Small, David
    Wang, Hangjun
    Kasymjanova, Goulnar
    Spatz, Alan
    Cohen, Victor
    CURRENT ONCOLOGY, 2022, 29 (02) : 1107 - 1116
  • [50] Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
    Agulnik, J.
    Kasymjanova, G.
    Small, D.
    Pepe, C.
    Sakr, L.
    Chong, G.
    Wang, H.
    Papadakis, A.
    Spatz, A.
    Cohen, V.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S378 - S378
12345